<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363945</url>
  </required_header>
  <id_info>
    <org_study_id>MDR-101-MLK</org_study_id>
    <nct_id>NCT03363945</nct_id>
  </id_info>
  <brief_title>Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants</brief_title>
  <official_title>A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medeor Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medeor Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the safety and efficacy of cellular&#xD;
      immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of&#xD;
      human leukocyte antigen (HLA)-matched, living donor kidney transplants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, patients receiving a transplanted kidney are required to take life-long&#xD;
      immunosuppressive medications to prevent rejection of the transplanted kidney. These&#xD;
      medications carry substantial side effects. In addition, these medicines often do not&#xD;
      completely control damage to the kidney from the recipients' immune system, ultimately&#xD;
      causing the kidney to fail.&#xD;
&#xD;
      Medeor Therapeutics is developing a novel cell-based therapy to reprogram the recipients'&#xD;
      immune system to accept a transplanted kidney without the need for long term use of&#xD;
      immunosuppression drugs.&#xD;
&#xD;
      The purpose of the current Phase 3 study is to demonstrate the efficacy and safety of MDR-101&#xD;
      for the induction of transplant immune tolerance in a prospective, randomized, multicenter&#xD;
      clinical trial. MDR-101 is intended to induce mixed lymphohematopoietic chimerism and donor&#xD;
      specific immune tolerance in order to preserve transplant kidney function, avert transplant&#xD;
      kidney rejection, and eliminate the cumulative and serious side effects associated with&#xD;
      immunosuppressive drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Total lymphoid irradiation and anti-thymocyte globulin</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional immune tolerance defined as</measure>
    <time_frame>Up to 36 months post-kidney transplant</time_frame>
    <description>Achievement of the required duration of persistent donor mixed chimerism to permit calcineurin inhibitor immunosuppressive withdrawal beginning at 6-7 months post-kidney transplant surgery, and&#xD;
Successful withdrawal from all immunosuppressives by at least 12 months post-kidney transplant surgery, and&#xD;
Subsequent successful maintenance off all immunosuppressive drugs for at least 24 additional months (out to at least 36 months post-kidney transplant surgery) without biopsy-proven acute rejection, de novo Donor Specific Antibody, transplant kidney loss, or subject death. Loss to follow-up will be adjudicated as a failure in intent-to-treat analysis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>MDR-101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose will be administered via IV infusion post-kidney transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized to this arm will receive the standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDR-101</intervention_name>
    <description>Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells</description>
    <arm_group_label>MDR-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria:&#xD;
&#xD;
          -  Planned recipient of a first kidney allograft from an HLA-matched, living related&#xD;
             donor&#xD;
&#xD;
          -  Age ≥18 and ≤70 years&#xD;
&#xD;
          -  Single solid organ recipient (kidney only)&#xD;
&#xD;
          -  ABO matched with donor&#xD;
&#xD;
        Recipient Exclusion Criteria:&#xD;
&#xD;
          -  Underlying kidney disease with a high risk of disease recurrence in the transplanted&#xD;
             kidney&#xD;
&#xD;
          -  Baseline positive donor-specific anti-HLA antibody testing&#xD;
&#xD;
          -  Is taking immunosuppressive therapy&#xD;
&#xD;
          -  Evidence of prior hepatitis B (HBV) or hepatitis C (HCV)&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          -  HLA-matched first degree (parent, child or sibling) or second-degree (child of a&#xD;
             sibling or half sibling) relative of the prospective recipient participant&#xD;
&#xD;
          -  Age ≥18 and ≤70 years&#xD;
&#xD;
          -  Prepared to be a living related kidney donor, and capable of undergoing G-CSF&#xD;
             mobilization and apheresis of hematopoietic cells&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  History of autoimmune disorders&#xD;
&#xD;
          -  History of type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Tests confirmed positive for human immunodeficiency virus (HIV), HBV, HCV, T. cruzi,&#xD;
             or syphilis&#xD;
&#xD;
          -  History of infection with Zika virus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Crowley, MS, BSN</last_name>
    <role>Study Director</role>
    <affiliation>Medeor Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153-3328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RWJBarnabas Health</name>
      <address>
        <city>Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Transplant Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INOVA Fairfax Hospital</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Est- de-l'Île-de-Montréal Installation Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>cellular therapy</keyword>
  <keyword>anti-rejection therapy</keyword>
  <keyword>living donor</keyword>
  <keyword>HLA-matched</keyword>
  <keyword>hematopoietic stem cells (HSC)</keyword>
  <keyword>CD34+</keyword>
  <keyword>CD3+</keyword>
  <keyword>T cells</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

